RJ Hamster
IPO Season Could Return in 2026
You are receiving this email because you are subscribed to Behind the Markets. If you no longer wish to receive these emails, please unsubscribe here.
Prefer to view this content on our website? Click here.
How to Trade SpaceX Without Trading SpaceX
IPOs are exciting for a reason: they create scarcity, headlines, and the promise of getting in early on “the next big thing.”
They’re also a coin flip.
Some IPOs roar out of the gate and never look back. Others open strong, fade fast, and punish late buyers who chased hype instead of fundamentals. Even well-known brands can disappoint once the roadshow excitement wears off and lockups, valuations, and reality set in.
That’s why one of the most effective ways to invest in an IPO—especially a high-profile one—is not to invest in the IPO directly.
The SpaceX buzz is building again
SpaceX has been one of the most anticipated IPO candidates in the world. And lately, that speculation has intensified.
A Reuters-sourced report published via Yahoo Finance said SpaceX has explored a blockbuster 2026 IPO that could raise more than $25 billion, potentially pushing valuation toward or above $1 trillion. That’s not a “routine” listing—if it happens, it could reshape the entire IPO calendar and spark a broader reopening of the new-issues market.
The potential appeal is obvious:
- SpaceX is the dominant U.S. private-space company by profile and launch cadence.
- Starlink continues to scale as a global satellite-internet business.
- Long-term ambitions (including Starship) keep the growth narrative alive.
The problem is that IPO timing and pricing are unknowable until they aren’t—by which point most of the “easy upside” is often already priced into the stock.
Sponsored by Decentralized Masters
The Fed is Trapped. Here’s Your Only Exit Strategy.
Every 8 hours, the U.S. adds $1B to the national debt. We’re at 120% debt-to-GDP. Greece collapsed at 130%. The Fed can’t win: cut rates, inflation spikes. Keep rates high, the debt spiral accelerates. Either way, your savings lose. A CFA Charterholder and ex-Wall Street banker built a 3-phase system that works regardless of which path the Fed chooses. Over 4,000 investors are using it now.
Watch the free training to see the ABN System that protects you from what’s coming →
Why IPO investing can be brutal
Even when the company is real, the “IPO trade” has structural risks:
- Valuation risk
Investment banks and selling shareholders generally want the highest possible price. That can mean IPO buyers pay full freight. - Volatility and liquidity traps
Early trading can be thin and emotional. Price swings can be violent, especially in a market that’s risk-sensitive. - Lockup dynamics
When lockups expire, early investors and insiders may sell. That supply can pressure shares regardless of business quality. - Hype cycles
Media attention often peaks at the IPO—not when fundamentals are best.
So instead of betting everything on one listing at one price on one day, it can make more sense to position for the broader IPO cycle—the environment that tends to benefit from a reopened new-issues market.
That’s where IPO-focused ETFs come in.
ETF: First Trust US Equity Opportunities ETF (SYM: FPX)
The diversified “U.S. IPO leaders” approach
FPX is built to provide exposure to U.S. companies relatively early in their public life, using a rules-based approach rather than single-stock guessing. First Trust describes FPX as an ETF designed around U.S. IPO exposure (and provides fund materials and index details through its official product page).
Why FPX can be useful in an IPO cycle
- Diversification: exposure to multiple newly public companies rather than a single IPO outcome.
- Rules-based construction: less reliance on narrative timing.
- Theme leverage: if the IPO market reopens, the “new listing ecosystem” often attracts incremental capital.
FPX last traded around $165.00.
Tradeoff to understand: FPX is not a direct SpaceX proxy. If SpaceX stays private—or if the listing comes with unexpected structure—FPX still functions as a broader IPO-cycle vehicle rather than a one-off bet.
Huge Alerts
BioStem Technologies (OTCQB: BSEM) is emerging as one of the most compelling small-cap MedTech companies as 2026 begins. The company just completed the acquisition of BioTissue Holdings’ surgical and wound care business, instantly expanding its footprint into hospital-based, acute, and surgical wound care.
With established product lines like Neox® and Clarix®, a nationwide sales force, and key GPO contracts, BioStem is now positioned to capture a $300–$350 million addressable market, spanning chronic and acute wound care, burns, and soft-tissue repair.
Zacks Small Cap Research has assigned BSEM a $25.50 price target, highlighting confidence in the company’s profitable growth, clinical validation, and expanding market presence.
Coupled with seven consecutive profitable quarters, strong gross margins of 88.5%, and $16 million in cash post-acquisition, BSEM is demonstrating operational excellence rarely seen in small-cap regenerative medicine.
Backed by clinically validated BioREtain® technology, FDA-level studies, and a potential Nasdaq uplisting in mid-2026, BSEM is gaining traction with both institutional investors and healthcare providers.
Discover why BSEM is setting the standard for profitable, clinically proven MedTech growth in 2026
ETF: Renaissance IPO ETF (SYM: IPO)
The “newly public basket” designed to reduce single-stock risk
For investors who want a clean, index-driven way to own newly public companies, Renaissance’s IPO ETF is one of the better-known options.
Renaissance explicitly states the fund “seeks to provide investors with the largest, most liquid US-listed newly public company stocks in one security,” aiming to reduce single-stock risk and avoid overlap with major core indices.
Additional index details commonly cited for IPO-focused funds: the ETF is based on the FTSE Renaissance IPO Indexand generally holds companies for a defined window after they go public (often up to three years), then rotates them out.
IPO last traded around $44.09.
Why IPO can work well for this theme
- Focuses on liquid newly public names (important—because many new listings trade poorly at first).
- Uses an index approach that can benefit from multiple winnersrather than needing one perfect call.
How this becomes a “SpaceX strategy” without SpaceX
If SpaceX truly moves toward a 2026 IPO with a $25B+ raise, that kind of deal can do more than create one tradable ticker—it can help reopen the IPO window for other high-profile private companies.
In that environment:
- investor appetite for new listings can improve,
- flows can rotate into “newly public” baskets, and
- IPO-themed ETFs can benefit from the broader cycle.
This is the central idea: instead of trying to win the IPO coin flip, it’s often more sensible to position for the second-order effect—the return of a more active IPO market.
TradeAlgo
Just Out: New AI Tool for Retail Traders
Peter Lynch generated 29.2% annual returns (1977-1990) with one philosophy: “The person who turns over the most rocks wins.” Hedge funds have analyst teams to uncover opportunities—retail traders typically don’t.
TradeAlgo changes that with AI-powered dark pool alerts. The system scans secret exchanges for unusual stock activity and texts you exact tickers, letting you spot volume surges and potential breakouts instantly.
Are there any other IPO rumors you’re keeping an eye on? What other sectors of the market are you focusing on in 2026? Hit “reply” to this email and let us know your thoughts!
We are issuing this disclosure in compliance with Section 17(b) of the Securities Act, which requires us to disclose any compensation received or expected to be received in cash or in kind in connection with the purchase or sale of any security.
We would like to inform you that we have received or expect to receive compensation in connection with the purchase or sale of the securities of BioStem Technologies Inc. (OTC: BSEM) . The compensation consists of up to $6,500 and was received/will be received from Sideways Frequency.
This communication should not be considered as an endorsement of the securities of BioStem Technologies Inc. (OTC: BSEM) and we are not responsible for any errors or omissions in any information provided about the securities of BioStem Technologies Inc. (OTC: BSEM) by Huge Alerts.
We encourage you to conduct your own due diligence and research before making any investment decisions. You should also consult with a financial advisor before making any investment decisions.
This disclosure is made as of 02/12/2026.
Our mailing address is:
Behind the Markets, LLC
4260 NW 1st Avenue, Suite 55
Boca Raton, FL 33431
Copyright © 2024 Behind the Markets, LLC, All rights reserved.
You’re receiving this email as part of your subscription to Behind the Markets. For more information about our privacy practices, please review our Privacy Policy or our Legal Notices.
Behind the Markets
